We are live on ! Find out more

Bausch Health

BHC

Market cap $2.11B

5.65 USD

-0.04

0.7%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

5.79

+0.14

2.48%

1 day

-0.7%

5 days

-7.68%

1 month

-14.13%

3 months

18.7%

6 months

9.07%

Year to date

-21.64%

1 year

-17.28%

5 years

-79.28%

10 years

-79.15%

About: Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.

Employees: 20,300

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 47.6%

Neutral 47.6%

Negative 4.8%

Zacks Investment Research

4 Healthcare Stocks to Play Safe as Fed Gears Up for Rate Hike

AMGN, BHC, CDNA and CNC offer defensive healthcare plays as inflation climbs and the Fed readies for a possible rate hike.

4 Healthcare Stocks to Play Safe as Fed Gears Up for Rate Hike

Bausch Health and YUN Announce Expansion to Mexico and Across Additional EMEA Markets

Collaboration expands access to science-led, microbiome-friendly skincare solutions in Mexico and across new markets in EMEA, including launches in the Czech Republic, Slovakia, Ukraine, Bulgaria and Kazakhstan. LAVAL, QC, Sept.

Bausch Health and YUN Announce Expansion to Mexico and Across Additional EMEA Markets

Bausch Health's Ortho Dermatologics Announces the 2026 Aspire Higher Scholarship Winners

This year's Aspire Higher scholarships are awarded to six students who have been affected by dermatologic conditions. LAVAL, QC, Aug. 27, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and its dermatology business, Ortho Dermatologics, today announced the recipients of its 2026 Aspire Higher Scholarship Program.

Bausch Health's Ortho Dermatologics Announces the 2026 Aspire Higher Scholarship Winners

Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that two of its pharmaceutical pipeline assets – both first-in-class treatments – will advance to new trials based on recent clinical results. “Helping people see better to live better starts with tackling the challenges patients still face every day,” said Bausch + Lomb CEO Brent Saunders. “These results suppor.

Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results

Zacks Investment Research

Can Bausch (BHC) Run Higher on Rising Earnings Estimates?

Bausch Health (BHC) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Can Bausch (BHC) Run Higher on Rising Earnings Estimates?

Zacks Investment Research

Bausch (BHC) Upgraded to Buy: Here's What You Should Know

Bausch (BHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Bausch (BHC) Upgraded to Buy: Here's What You Should Know

Bausch + Lomb: The Market Is Pricing The Balance Sheet, Not The Eye-Care Engine

Bausch + Lomb is positioned as a turnaround and deleveraging opportunity, benefiting from a shift toward higher-margin products and expanding global distribution. Q2 2026 results showed broad-based revenue growth (9% YoY), significant margin expansion, and strong operating cash flow, supporting an optimistic outlook. Premium intraocular lenses and branded pharmaceuticals are driving faster growth, improving mix, and enabling margin and EBITDA expansion without unsustainable revenue acceleration.

Bausch + Lomb: The Market Is Pricing The Balance Sheet, Not The Eye-Care Engine

Bausch Health Announces 2026 Gastrointestinal Health Scholars Program Winners

For the Seventh Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 Scholarship LAVAL, QC, Aug. 17, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the recipients of its 2026 Salix Gastrointestinal Health Scholars Program. For the seventh year, Bausch Health is proud to award 10 deserving students living with a GI disease $10,000 each to further their higher education.

Bausch Health Announces 2026 Gastrointestinal Health Scholars Program Winners

Bausch Health: Q2 Beat And Cheap, But Debt Overhang Remains Substantial

Bausch Health Companies Inc. has surged 40% post-Q2 on strong results and raised FY2026 guidance, but balance sheet risks remain paramount. BHC delivered Q2 non-GAAP EPS of $1.26, beating consensus by $0.25, with 13% revenue growth and notable margin and cash flow improvements. Despite operational momentum, BHC's $15B long-term debt and $800M H1 interest expense drive speculative credit ratings and analyst skepticism.

Bausch Health: Q2 Beat And Cheap, But Debt Overhang Remains Substantial

Zacks Investment Research

Why Bausch Health (BHC) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Bausch Health (BHC) is a Top Momentum Stock for the Long-Term

See News Rankings

Price charts implemented using Lightweight Charts™